- Home
- REFI vs AURA Comparison
REFI vs AURA Comparison
Compare REFI & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- AURA
- Stock Information
- Founded
- REFI 2021
- AURA 2007
- Country
- REFI United States
- AURA United States
- Employees
- REFI N/A
- AURA N/A
- Industry
- REFI Real Estate Investment Trusts
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- AURA Health Care
- Exchange
- REFI Nasdaq
- AURA Nasdaq
- Market Cap
- REFI 314.2M
- AURA 370.1M
- IPO Year
- REFI 2021
- AURA 2021
- Fundamental
- Price
- REFI $13.91
- AURA $5.36
- Analyst Decision
- REFI Strong Buy
- AURA Strong Buy
- Analyst Count
- REFI 3
- AURA 4
- Target Price
- REFI $20.00
- AURA $22.75
- AVG Volume (30 Days)
- REFI 184.0K
- AURA 482.7K
- Earning Date
- REFI 05-07-2025
- AURA 05-08-2025
- Dividend Yield
- REFI 14.86%
- AURA N/A
- EPS Growth
- REFI N/A
- AURA N/A
- EPS
- REFI 1.88
- AURA N/A
- Revenue
- REFI $55,534,183.00
- AURA N/A
- Revenue This Year
- REFI $17.87
- AURA N/A
- Revenue Next Year
- REFI N/A
- AURA N/A
- P/E Ratio
- REFI $7.40
- AURA N/A
- Revenue Growth
- REFI N/A
- AURA N/A
- 52 Week Low
- REFI $12.76
- AURA $4.84
- 52 Week High
- REFI $16.47
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- REFI 35.57
- AURA 37.19
- Support Level
- REFI $12.76
- AURA $4.84
- Resistance Level
- REFI $14.24
- AURA $5.82
- Average True Range (ATR)
- REFI 0.51
- AURA 0.48
- MACD
- REFI -0.01
- AURA 0.03
- Stochastic Oscillator
- REFI 51.57
- AURA 32.20
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.